These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 34927668)

  • 1. TMBleR: a bioinformatic tool to optimize TMB estimation and predictive power.
    Fancello L; Guida A; Frige G; Ceol AGM; Babini G; Scaglione GL; Zanfardino M; Mazza T; Ferrando L; Pelicci PG; Mazzarella L
    Bioinformatics; 2022 Mar; 38(6):1724-1726. PubMed ID: 34927668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges.
    Fancello L; Gandini S; Pelicci PG; Mazzarella L
    J Immunother Cancer; 2019 Jul; 7(1):183. PubMed ID: 31307554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing panel-based tumor mutational burden (TMB) measurement.
    Budczies J; Allgäuer M; Litchfield K; Rempel E; Christopoulos P; Kazdal D; Endris V; Thomas M; Fröhling S; Peters S; Swanton C; Schirmacher P; Stenzinger A
    Ann Oncol; 2019 Sep; 30(9):1496-1506. PubMed ID: 31268125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.
    Endris V; Buchhalter I; Allgäuer M; Rempel E; Lier A; Volckmar AL; Kirchner M; von Winterfeld M; Leichsenring J; Neumann O; Penzel R; Weichert W; Glimm H; Fröhling S; Winter H; Herth F; Thomas M; Schirmacher P; Budczies J; Stenzinger A
    Int J Cancer; 2019 May; 144(9):2303-2312. PubMed ID: 30446996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessments of tumor mutational burden estimation by targeted panel sequencing: A comprehensive simulation analysis.
    Li D; Wang D; Johann DJ; Hong H; Xu J
    Exp Biol Med (Maywood); 2023 Nov; 248(21):1918-1926. PubMed ID: 38062992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
    Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
    BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis.
    Buchhalter I; Rempel E; Endris V; Allgäuer M; Neumann O; Volckmar AL; Kirchner M; Leichsenring J; Lier A; von Winterfeld M; Penzel R; Christopoulos P; Thomas M; Fröhling S; Schirmacher P; Budczies J; Stenzinger A
    Int J Cancer; 2019 Feb; 144(4):848-858. PubMed ID: 30238975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB.
    Sung MT; Wang YH; Li CF
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing the evaluation of gene-targeted panels for tumor mutational burden estimation.
    Li Y; Luo Y
    Sci Rep; 2021 Oct; 11(1):21072. PubMed ID: 34702927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
    Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
    JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project.
    Vega DM; Yee LM; McShane LM; Williams PM; Chen L; Vilimas T; Fabrizio D; Funari V; Newberg J; Bruce LK; Chen SJ; Baden J; Carl Barrett J; Beer P; Butler M; Cheng JH; Conroy J; Cyanam D; Eyring K; Garcia E; Green G; Gregersen VR; Hellmann MD; Keefer LA; Lasiter L; Lazar AJ; Li MC; MacConaill LE; Meier K; Mellert H; Pabla S; Pallavajjalla A; Pestano G; Salgado R; Samara R; Sokol ES; Stafford P; Budczies J; Stenzinger A; Tom W; Valkenburg KC; Wang XZ; Weigman V; Xie M; Xie Q; Zehir A; Zhao C; Zhao Y; Stewart MD; Allen J;
    Ann Oncol; 2021 Dec; 32(12):1626-1636. PubMed ID: 34606929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer.
    Park S; Lee C; Ku BM; Kim M; Park WY; Kim NKD; Ahn MJ
    BMB Rep; 2021 Jul; 54(7):386-391. PubMed ID: 34154699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing.
    Wang HY; Deng L; Li YQ; Zhang X; Long YK; Zhang X; Feng YF; He Y; Tang T; Yang XH; Wang F
    Cancer Res Treat; 2021 Oct; 53(4):973-982. PubMed ID: 33677848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benchmarking bioinformatics approaches for tumour mutational burden evaluation from a large cancer panel against whole-exome sequencing.
    Pang J; Xia H; Mi S; Zhang W; Pendrick D; Freeman C; Fernandes H; Mansukhani M; Hsiao SJ
    J Clin Pathol; 2023 Apr; 76(4):276-280. PubMed ID: 35906043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing gene panels for tumor mutational burden estimation: the need to shift from 'correlation' to 'accuracy'.
    Wu HX; Wang ZX; Zhao Q; Wang F; Xu RH
    J Immunother Cancer; 2019 Aug; 7(1):206. PubMed ID: 31387639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Mutation Burden as a Cornerstone in Precision Oncology Landscapes: Effect of Panel Size and Uncertainty in Cutoffs.
    Budak B; Arga KY
    OMICS; 2024 Apr; 28(4):193-203. PubMed ID: 38657109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of high tumor mutational burden in solid tumors and challenges for biomarker application.
    McNamara MG; Jacobs T; Lamarca A; Hubner RA; Valle JW; Amir E
    Cancer Treat Rev; 2020 Sep; 89():102084. PubMed ID: 32738738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Tumor Mutational Burden in Pediatric Tumors by Real-Life Whole-Exome Sequencing and In Silico Simulation of Targeted Gene Panels: How the Choice of Method Could Affect the Clinical Decision?
    Noskova H; Kyr M; Pal K; Merta T; Mudry P; Polaskova K; Ivkovic TC; Adamcova S; Hornakova T; Jezova M; Kren L; Sterba J; Slaby O
    Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31963488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions.
    Stenzinger A; Allen JD; Maas J; Stewart MD; Merino DM; Wempe MM; Dietel M
    Genes Chromosomes Cancer; 2019 Aug; 58(8):578-588. PubMed ID: 30664300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.